Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A comprehensive urine workflow enables robust methylation and fragmentation analysis of cell-free DNA.

Scientific reports·2026

Same author

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.

NPJ breast cancer·2026

Same author

Reference materials and external quality assessment for liquid biopsy assays: Expert opinions from the European Liquid Biopsy Society ctDNA workshop.

Cancer treatment and research communications·2026

Same author

Listening to the bladder field: Urine liquid biopsies reveal differential treatment responses in NMIBC.

Cell·2026

Same author

Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.

British journal of cancer·2026

Same author

Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology.

Molecular oncology·2025

Same journal

Cardiovascular disease and miRNA.

Advances in clinical chemistry·2026

Same journal

RNA biomarkers in antidoping.

Advances in clinical chemistry·2026

Same journal

Biomarkers for assessing magnesium status.

Advances in clinical chemistry·2026

Same journal

Advances in microfluidic extracellular vesicle technology.

Advances in clinical chemistry·2026

Same journal

Chronic low-grade inflammation in vegetarians and vegans: Biomarker evidence and methodological considerations.

Advances in clinical chemistry·2026

Same journal

Biomarkers in heart failure.

Advances in clinical chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 3, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Advances in Circulating Tumor DNA Analysis.

Samantha Perakis¹, Martina Auer¹, Jelena Belic¹

¹Institute of Human Genetics, Medical University of Graz, Graz, Austria.

Advances in Clinical Chemistry

|April 23, 2017

Summary

This summary is machine-generated.

Analyzing cell-free circulating tumor DNA (ctDNA), or liquid biopsy, offers continuous cancer monitoring. Advances in ctDNA analysis are paving the way for its clinical implementation in early detection and treatment assessment.

Keywords:

Assessment of treatment response Cell-free circulating tumor DNA Identification of minimal residual disease Monitoring tumor evolution Predictive Prognostic biomarker ctDNA

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Related Experiment Videos

Last Updated: Mar 3, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Cell-free circulating tumor DNA (ctDNA) analysis, or liquid biopsy, shows promise for cancer care.
It offers continuous monitoring of tumor changes, unlike traditional tissue biopsies.
Technological advancements are making ctDNA analysis more accessible for clinical use.

Purpose of the Study:

To summarize recent advances in ctDNA analysis.
To cover the journey from ctDNA discovery to its clinical applications.
To highlight the potential of ctDNA in revolutionizing cancer management.

Main Methods:

Review of ctDNA discovery and evolution.
Discussion of methodological approaches for ctDNA analysis.
Exploration of clinical applicability and implementation.

Main Results:

ctDNA analysis enables early cancer detection.
It aids in identifying minimal residual disease.
It assists in assessing treatment response and monitoring tumor evolution.

Conclusions:

ctDNA analysis is a powerful tool for comprehensive cancer management.
Ongoing research and standardization are crucial for widespread clinical adoption.
Liquid biopsy represents a significant step forward in personalized oncology.